Dr. Mohty started his career in academia with a focus on translational research related to the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs, and hypomethylating agents. His research has also included the development of reduced-toxicity conditioning regimens, immunotherapy, and other aspects of therapy for acute leukemia and multiple myeloma. More recently, he pioneered a cutting-edge research dedicated to the modulation of the microbiota in patients with hematological malignancies.